Conclusion
Both the Xen gel stent and PreserFlo MicroShunt have demonstrated promise for a wide application for glaucoma patients with a range of glaucoma severity and medication burden. These devices provide patients with IOP lowering effects similar to traditional incisional surgery such as trabeculectomy or tube shunt surgery, but with fewer risks than these more invasive alternatives. These devices have demonstrated impressive efficacy so far and decrease the risk of both early and late hypotony because of their valve-less intrinsic flow-limiting design. Still, there need to be additional randomized, prospective studies comparing these gel stents and microshunts both to each other and to other traditional glaucoma surgeries.
Acknowledgements
None.
Financial support and sponsorship
The work was supported by the Department of Ophthalmology, NYU Langone Health.
Curr Opin Ophthalmol. 2020;31(2):132-138. © 2020 Lippincott Williams & Wilkins
Comments